The proposed Drug Resistance Index (DRI) is not a good measure of antibiotic effectiveness in relation to drug resistance

  30 August 2019

The conclude that the DRI in its present form is not a useful tool to communicate to a wide audience. First, because its complexity makes it difficult to interpret, and second because the DRI may promote the unnecessary use of broad-spectrum antibiotics, potentially reversing many good initiatives undertaken to overcome and counter the global problem of antimicrobial resistance.

Further reading: BMJ Global Health
Author(s): Christina M J E Vandenbroucke-Grauls, Gunnar Kahlmeter, Jan Kluytmans, Marjolein Kluytmans-van den Bergh, Dominique L Monnet, Gunnar Skov Simonsen, Robert L Skov, Ute Wolff Sönksen, Andreas Voss
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Your Biweekly Source for Global AMR Insights!

Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.

Don’t miss out on staying ahead in the global AMR movement—subscribe now!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed